Why the study?
Does a personalized pharmacogenetic approach reduce the incidence of statin-associated muscle symptoms and optimize adherence in patients with or at risk of ASCVD?
Does a personalized pharmacogenetic approach reduce the incidence of statin-associated muscle symptoms and optimize adherence in patients with or at risk of ASCVD?
Understanding the pharmacogenetic basis of statin-associated muscle symptoms may enable personalized approaches to improve statin adherence and reduce cardiovascular risk.
Answers are grounded in this paper and cite their sources.
SAMS variability supports individualized adherence counseling; leaves open genetic contributions pending prospective validation.
Statin therapy reduces cardiovascular events in patients with, or at risk of, atherosclerotic cardiovascular disease. However, statins are underutilized in patients for whom they are indicated and are frequently discontinued. Discontinuation may be the result of statin-associated muscle symptoms (SAMS), which encompass a broad spectrum of clinical phenotypes from myalgia to severe myopathy. As with many adverse drug reactions (ADRs), inter-individual variability in susceptibility to SAMS is due, at least in part, to differences in host genetics. The genetic basis for SAMS has been investigated in candidate gene studies, genome-wide association studies, and, more recently, studies of multi-omic networks, including at the transcriptome level. In this article, we provide a systematic review of the pharmacogenetic basis of SAMS, focusing on how an understanding of the genetic and molecular determinants of SAMS can be considered in a personalized approach to reduce the incidence of this ADR, optimize statin adherence, and reduce the risk for cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Brunham et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: